GlaxoSmithKline Pharmaceuticals quarterly results and financials

GlaxoSmithKline Pharmaceuticals (GLAXO)₹2,710+6.71%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), GlaxoSmithKline Pharmaceuticals reported sales of ₹937 Cr, up 16.6% from Jun 2025, and net profit of ₹237 Cr, up 15.6% year on year. For the year to Mar 2026, sales were ₹3,818 Cr and net profit ₹1,038 Cr.

Sales (Jun 2026): ₹937 Cr
Net profit (Jun 2026): ₹237 Cr
Sales (FY Mar 2026): ₹3,818 Cr
Net profit (FY Mar 2026): ₹1,038 Cr
EPS (Jun 2026): ₹14.04
Borrowings (Mar 2026): ₹32.93 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

GlaxoSmithKline Pharmaceuticals quarterly results

₹ crore unless stated; each column is a quarter.

GlaxoSmithKline Pharmaceuticals Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	955	804	929	813	1,010	948	973	804	978	1,040	994	937
Expenses	670	590	676	586	691	661	644	556	647	672	647	646
Operating Profit	290	218	258	232	323	293	334	252	337	372	352	297
OPM %	30.0%	27.0%	28.0%	28.0%	32.0%	31.1%	34.0%	31.0%	34.0%	36.0%	35.0%	31.0%
Other Income	27.91	−134	31.90	35.86	38.84	34.87	40.84	43.86	35.89	49.80	35.86	43.85
Interest	0.00	0.00	1.01	0.00	0.00	0.00	1.01	0.00	1.01	1.01	1.01	1.01
Depreciation	18.02	17.03	18.04	16.04	17.04	19.02	15.03	16.02	17.03	20.03	13.03	16.04
Profit before tax	299	65.01	271	249	344	308	359	279	354	400	373	322
Tax %	27.1%	30.0%	28.1%	27.0%	27.0%	25.0%	27.0%	27.0%	27.0%	26.0%	26.0%	26.0%
Exceptional items	0.00	−132	2.01	0.00	3.01	0.00	0.00	0.00	2.01	13.02	0.00	0.00
Net Profit	218	46.04	194	182	252	230	264	205	258	297	279	237
EPS (Rs)	12.88	2.71	11.51	10.80	14.97	13.62	15.56	12.13	15.25	17.52	16.46	14.04

GlaxoSmithKline Pharmaceuticals profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

GlaxoSmithKline Pharmaceuticals Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	2,836	2,906	2,865	3,126	3,220	2,921	3,275	3,249	3,451	3,745	3,818	3,949
Expenses	2,371	2,500	2,372	2,536	2,576	2,335	2,525	2,457	2,556	2,581	2,524	2,612
Operating Profit	479	421	509	602	658	600	764	806	911	1,181	1,313	1,358
OPM %	17.0%	14.0%	18.0%	19.0%	20.0%	20.0%	23.0%	25.0%	26.0%	31.0%	34.0%	34.4%
Other Income	125	119	69.72	130	−261	8.96	1,397	103	−20.94	148	165	165
Interest	0.00	0.00	0.00	1.01	6.02	4.01	2.01	2.01	2.01	1.01	3.01	4.04
Depreciation	25.05	27.04	38.05	49.13	83.14	79.18	68.08	66.15	70.14	67.14	66.17	66.13
Profit before tax	578	511	540	683	306	525	2,092	839	816	1,260	1,407	1,449
Tax %	35.0%	34.0%	35.0%	35.0%	70.0%	32.0%	19.0%	27.0%	28.1%	26.0%	26.0%	—
Exceptional items	2.01	30.02	10.01	20.03	−51.06	−118	11.01	21.02	−67.02	54.10	74.11	15.03
Net Profit	377	338	351	446	93.14	359	1,699	612	591	930	1,038	1,070
EPS (Rs)	22.28	19.94	20.77	26.36	5.52	21.20	100.42	36.16	34.92	54.90	61.37	63.27
Dividend payout %	113.0%	75.0%	85.0%	76.0%	727.0%	142.0%	90.0%	89.0%	92.0%	99.0%	93.0%	—

GlaxoSmithKline Pharmaceuticals balance sheet

₹ crore, at each year end.

GlaxoSmithKline Pharmaceuticals Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	84.68	84.73	84.70	84.71	168	168	168	168	169	169	168	168
Reserves	1,748	2,102	1,927	1,978	1,975	1,656	1,313	2,500	1,577	1,613	1,788	2,105
Borrowings	2.99	1.99	1.99	0.99	0.99	0.00	34.96	19.96	15.98	18.96	9.99	32.93
Other Liabilities	1,377	865	990	1,884	1,768	1,309	1,598	1,945	1,564	1,757	2,143	2,019
Total Liabilities	3,213	3,053	3,004	3,946	3,913	3,134	3,114	4,633	3,325	3,559	4,110	4,327
Fixed Assets	123	204	258	325	432	757	387	331	330	321	284	281
CWIP	115	269	606	925	1,005	120	13.02	30.06	20.05	14.02	14.03	33.08
Investments	0.00	6.02	0.00	0.00	0.00	0.00	0.00	367	519	815	1,120	1,396
Other Assets	2,974	2,575	2,139	2,698	2,477	2,256	2,714	3,907	2,455	2,408	2,691	2,617
Inventories	374	524	424	498	484	481	545	533	458	523	481	456
Trade receivables	100	127	171	147	120	100	216	206	192	222	293	273
Cash & equivalents	1,915	1,394	902	1,299	1,173	1,085	1,161	2,493	1,160	1,066	1,407	1,394
Total Assets	3,213	3,053	3,004	3,946	3,913	3,134	3,114	4,633	3,325	3,559	4,110	4,327

GlaxoSmithKline Pharmaceuticals cash flow

₹ crore, for each year.

GlaxoSmithKline Pharmaceuticals Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	337	139	233	472	408	489	576	809	482	580	1,286	901
Cash from investing activity	180	499	301	−104	−153	−57.07	418	−406	809	9.01	−46.05	397
Cash from financing activity	−496	−637	−510	−307	−358	−427	−695	−523	−1,540	−562	−768	−736
Net cash flow	20.94	0.00	23.93	61.83	−102	5.98	299	−119	−250	28.92	473	561
Capex	164	233	305	405	292	156	44.14	35.10	44.17	31.13	23.07	55.19
Free cash flow	175	−69.16	−24.05	641	167	337	537	2,376	452	575	1,276	872
CFO / OP %	93.0%	72.0%	94.0%	132.9%	100.9%	102.9%	121.0%	121.9%	93.0%	91.9%	116.0%	93.0%

GlaxoSmithKline Pharmaceuticals ratios

Working-capital days and returns, by year.

GlaxoSmithKline Pharmaceuticals Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	12	17	22	20	15	12	28	24	23	24	29	27
Inventory days	90	155	110	146	130	134	158	143	130	143	125	123
Days payable	74	97	73	149	109	100	135	156	122	171	186	154
Cash conversion cycle	27	75	60	17	36	46	50	11	31	−4	−31	−4
Working capital days	−48	26	7	−90	−72	−38	−39	−94	−57	−64	−99	−91
ROCE %	42.0%	29.1%	22.0%	26.1%	31.1%	33.1%	38.0%	37.0%	36.0%	51.1%	63.0%	61.1%

GlaxoSmithKline Pharmaceuticals: frequently asked questions

What are the latest quarterly results of GlaxoSmithKline Pharmaceuticals?

For the Jun 2026 quarter, GlaxoSmithKline Pharmaceuticals reported sales of ₹937 Cr, up 16.6% year on year and net profit of ₹237 Cr, up 15.6% year on year. The operating margin was 31.0%.

What is the annual revenue of GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals' sales for the year to Mar 2026 were ₹3,818 Cr; over the last twelve months they were ₹3,949 Cr.

What is the net profit of GlaxoSmithKline Pharmaceuticals?

Net profit for the year to Mar 2026 was ₹1,038 Cr, and ₹1,070 Cr over the last twelve months. Earnings per share over the same trailing period were ₹63.27.

How much debt does GlaxoSmithKline Pharmaceuticals have?

GlaxoSmithKline Pharmaceuticals reported borrowings of ₹32.93 Cr at Mar 2026, against cash and equivalents of ₹1,394 Cr.

What is the free cash flow of GlaxoSmithKline Pharmaceuticals?

Cash from operations was ₹901 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹872 Cr.

Loading…